• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

News

Article

Daily Derm Times: April 14, 2025

Key Takeaways

  • Rosacea research is evolving with new treatments and a focus on inclusive, targeted approaches.
  • Systemic therapies for severe atopic dermatitis offer hope by addressing poor sleep, infections, and stunted development.
SHOW MORE

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times logo

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Rosacea: Progress, Challenges, and the Road Ahead

Experts explore how rosacea research is evolving, with new treatments, gaps in care, and a push for more inclusive, targeted approaches.

Systemic Therapies Offer New Hope for Severe AD

Untreated or undertreated AD can lead to poor sleep, infections, and stunted development.

Shea Butter-Based Emollient is Effective for Pediatric Erythema on Diapered Skin

The novel formulation was compared to a petrolatum-based diaper and was found to be just as effective for irritation and redness.

HyBryte Achieves 75% Treatment Success by Week 18 in Ongoing CTCL Trial

Interim FDA-funded study results show HyBryte delivers rapid, sustained response and strong safety in early-stage CTCL patients.

V-FC Handpiece Combines RF and Vacuum for Facial Contouring

Skin laxity improved by 34% with a moderate rate of improvement in female participants.

Women with Psoriasis More Likely to Discontinue Biologics Than Men, Study Finds

A recent study reveals that women with psoriasis are more likely to discontinue biologic treatments, including IL-17 and IL-23 inhibitors, due to adverse events and treatment dissatisfaction.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Videos
© 2025 MJH Life Sciences

All rights reserved.